Lipocine Inc (LPCN)

0.4549 +0.01  +2.22% NASDAQ Feb 14, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All LPCN News


View All Events


Date Type Description
03/06/2020 Earnings Lipocine Inc Fourth Quarter Earnings Results in 2019
11/12/2019 Earnings Lipocine Inc Third Quarter Earnings Results for 2019
08/07/2019 Earnings Lipocine Inc Second Quarter Earnings Results in 2019
06/12/2019 10:00 MDT Misc Lipocine Inc Annual General Meeting in 2018
05/08/2019 Earnings Lipocine Inc First Quarter Earnings Results in 2019
03/06/2019 Earnings Lipocine Inc Fourth Quarter Earnings Results in 2018
03/06/2019 Misc Lipocine Inc Annual Report in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports



  • URL:
  • Investor Relations URL:
  • HQ State/Province: Utah
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Mar. 06, 2020
  • Last Earnings Release: Nov. 12, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Lipocine Inc is a specialty pharmaceutical company focused on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its principal product candidate is TLANDO, an oral testosterone replacement therapy.





Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.